Get the Stockscreener App
4.99
1.96%
-0.10
Corvus Pharmaceuticals Inc stock is traded at $4.99, with a volume of 2.57M.
It is down -1.96% in the last 24 hours and down -39.44% over the past month.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
See More
Previous Close:
$5.09
Open:
$5.02
24h Volume:
2.57M
Relative Volume:
2.45
Market Cap:
$320.64M
Revenue:
-
Net Income/Loss:
$-27.03M
P/E Ratio:
-5.9405
EPS:
-0.84
Net Cash Flow:
$-23.97M
1W Performance:
-32.38%
1M Performance:
-39.44%
6M Performance:
+161.26%
1Y Performance:
+219.87%
1-Day Range:
$4.73
$5.34
1-Week Range:
$3.7701
$7.44
52-Week Range:
$1.30
$10.00
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Name
Corvus Pharmaceuticals Inc
Sector
Industry
Phone
(650) 900-4520
Address
863 MITTEN ROAD, BURLINGAME, CA
Compare CRVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
4.99 | 320.64M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-18-23 | Initiated | Oppenheimer | Outperform |
| Dec-01-21 | Resumed | Jefferies | Buy |
| May-27-21 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-10-21 | Downgrade | Mizuho | Buy → Neutral |
| Sep-12-19 | Initiated | Mizuho | Buy |
| May-29-19 | Initiated | ROTH Capital | Buy |
| Aug-24-17 | Upgrade | Credit Suisse | Underperform → Neutral |
| May-01-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-18-16 | Initiated | Credit Suisse | Outperform |
| Apr-18-16 | Initiated | Guggenheim | Buy |
View All
Corvus Pharmaceuticals Inc Stock (CRVS) Latest News
Corvus Pharmaceuticals (NASDAQ:CRVS) Announces Interim Data from Atopic Dermatitis TrialBURLINGAME, Calif. – Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) disclosed key interim data from its randomized, double-blind, placebo-controlled Phase 1 cl - Defense World
Corvus: Early Atopic Dermatitis Data Signals More Questions Than Answers (Rating Downgrade) - Seeking Alpha
Corvus Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:CRVS) - Defense World
Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday? - AOL
Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting (CRVS) - Seeking Alpha
Crude Oil Gains Over 1%, General Mills Shares Fall - Benzinga
Dow Surges 150 Points, US Current Account Deficit Widens In Q3 - Benzinga
Stock Traders Buy High Volume of Put Options on Corvus Pharmaceuticals (NASDAQ:CRVS) - MarketBeat
Corvus stock falls after eczema trial data (CRVS:NASDAQ) - Seeking Alpha
Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Corvus Pharmaceuticals Reports Promising Phase 1 Data and Financial Boost - TipRanks
Corvus Pharmaceuticals Shares Surge 7% After Positive Phase 1 Trial Results for Soquelitinib in Atopic Dermatitis - mediahousepress
Corvus Pharmaceuticals stock falls despite promising early trial results - Investing.com
Corvus Pharmaceuticals Announces Interim Data from - GlobeNewswire
Form 8-K Corvus Pharmaceuticals, For: Dec 18 - StreetInsider.com
Corvus Pharma's Atopic Dermatitis Drug Shows Promising 69% Efficacy in Phase 1 Trial Data - StockTitan
Why US Futures Are Rising WednesdayCorvus Pharma (NASDAQ:CRVS), Applied DNA Sciences (NASDAQ:APDN) - Benzinga
Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket - Benzinga
Corvus to share soquelitinib trial data for skin condition By Investing.com - Investing.com Australia
Corvus to share soquelitinib trial data for skin condition - Investing.com India
Stocks to Watch: Worthington Enterprises, Corvus Pharmaceuticals, CommScope Holding - MarketWatch
Corvus Pharmaceuticals Shares Rise 14% Ahead of Soquelitinib Trial Data Reveal - MarketWatch
Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024 - The Manila Times
Corvus Pharma Set to Unveil Key Atopic Dermatitis Trial Data for Soquelitinib in December - StockTitan
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Sees Large Increase in Short Interest - MarketBeat
Individual investors account for 50% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while private equity firms account for 16% - Yahoo Finance
Trading (CRVS) With Integrated Risk Controls - Stock Traders Daily
Point72 Asset Management L.P. Decreases Stock Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - MarketBeat
Individual investors are Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) biggest owners and were hit after market cap dropped US$89m - Simply Wall St
Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity - The Manila Times
CRVSCorvus Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Corvus Pharma's Cancer Drug Shows Breakthrough Immune Response in Nature Journal Study - StockTitan
Connor Clark & Lunn Investment Management Ltd. Grows Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - MarketBeat
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
FY2024 EPS Estimates for CRVS Cut by Cantor Fitzgerald - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2024 Earnings Call Transcript - MSN
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares Sold by Towerview LLC - MarketBeat
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis - The Manila Times
Corvus drug shows promise in systemic sclerosis models - Investing.com
Corvus' Soquelitinib Shows Promise in Preventing Systemic Sclerosis Lung Damage in Key Study | CRVS Stock News - StockTitan
Corvus Pharmaceuticals target raised to $13 by Jefferies - Investing.com UK
Corvus Pharmaceuticals: The Market Likes The Story (NASDAQ:CRVS) - Seeking Alpha
Earnings call: Corvus Pharmaceuticals reports Q3 financials and trial updates - Investing.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Given New $14.00 Price Target at Oppenheimer - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up Following Analyst Upgrade - MarketBeat
Corvus Pharmaceuticals Inc (CRVS) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid ... By GuruFocus - Investing.com Canada
Corvus Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks
Corvus: Q3 Earnings Snapshot - San Antonio Express-News
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results - The Manila Times
Corvus Pharma Reports $41.7M Cash Position, Advances Key Clinical Trials Despite Q3 Loss | CRVS Stock News - StockTitan
Corvus Pharmaceuticals Inc Stock (CRVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):